ASCO GU

The combination of cabozantinib and atezolizumab improved radiographic progression-free survival (rPFS) versus a switch to a second novel hormonal agent (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed on a first NHT, according to findings from the phase 3 CONTACT-02 trial. Read More ›

For the first time, an adjuvant treatment has led to a survival benefit in clear cell renal cell carcinoma (ccRCC). Data from the multicenter phase 3 KEYNOTE-564 study demonstrate that adjuvant pembrolizumab led to a 38% lower risk of death compared with placebo among patients with ccRCC who had a high risk of recurrence after surgery. The findings were presented by Toni K. Choueiri, MD, at the 2024 ASCO Genitourinary Cancers Symposium. Read More ›

A subcutaneous (SC) form of nivolumab was just as effective as IV nivolumab on progression-free survival (PFS) in patients with previously treated advanced renal cell carcinoma (ccRCC), with no increase in hypersensitivity reactions. The SC form is more convenient and less time consuming to administer, with an average administration time of 5 minutes or less. Read More ›